Compositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis

A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis comprising:

• administering to a subject a composition containing Siphoviridae bacteriophage Bac-FRP-5 and a pharmaceutically acceptable carrier,
• wherein the Siphoviridae bacteriophage Bac-FRP-5 is deposited in the Korean Collection for Type Culture (KCTC) under accession number KCTC 14403BP and has an ability to lyse the enterotoxigenic Bacteroides fragilis cells and the genome sequence as set forth in SEQ ID NO:
• 1,
• wherein the Siphoviridae bacteriophage Bac-FRP-5 has a latent period of 10-100 minutes and a burst size of 150-540 plaque-forming units (PFU)/infected cell,
• wherein the Siphoviridae bacteriophage Bac-FRP-5 has structural proteins in the size of approximately 42 kDa, 48 kDa, 63 kDa, 65 kDa, 75 kDa, 88 kDa, and 118 kDa;
• and
• wherein the composition has a concentration of Siphoviridae bacteriophage Bac-FRP-5 of 1×104 pfu/ml to 1×1015 pfu/ml or 1×104 pfu/g to 1×1015 pfu/g.